XSHG
600200
Market cap30mUSD
Dec 29, Last price
0.29CNY
Name
JiangSu WuZhong Pharmaceutical Development Co Ltd
Chart & performance
P/E
2.92
P/S
0.13
EPS
0.10
Div yield, %
—
Shrs. gr., 5y
-0.34%
Rev. gr., 5y
-5.40%
Revenues
1.60b
-28.64%
Net income
70m
P
CFO
-275m
L+34.85%
Dividend
Jun 15, 20180.056 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
JiangSu WuZhong Pharmaceutical Development Co., Ltd., along with its affiliated entities, operates as a diversified Chinese enterprise with interests spanning the pharmaceutical, real estate, and chemical industries. The company is actively involved in the research, production, and sale of a broad spectrum of pharmaceutical products. These include medications targeting infections, digestive ailments, cardiovascular and cerebrovascular conditions, viral diseases, vitamin deficiencies, and hemostasis. Its pharmaceutical offerings also encompass immunomodulators, featuring biopharmaceuticals, traditional chemical drugs, and contemporary Chinese medicines. These treatments are available in diverse formats, such as intravenous solutions, injectable powders and liquids, capsules, granular forms, tablets, emulsions, and oral liquid preparations. In its chemical division, the company focuses on the development, manufacturing, and distribution of various dyes and their intermediates. Additionally, its real estate arm undertakes the construction of both market-rate and subsidized residential properties. Founded in 1994, the company is based in Suzhou, China.
Key people
Qunshan Qian
Chairman of the Board, President, General Manager · since 2024
Xi Sun
Chief Financial Officer, Vice President, Deputy General Manager · since 2024
Tiejun Gu
Vice President, Deputy General Manager, Secretary of the Board · since 2024
Zhong Jiang
Director · since 2021
Qunying Qian
Vice Chairman of the Board · since 2024
Tianjiang Sun
Vice President, Deputy General Manager, Director · since 2024
Xin Tong
Director · since 2024
Feng Chen
Independent Director · since 2021
Liang Chen
Independent Director · since 2024
Ruoying Du
Independent Director · since 2024
Xiaolin Pan
Independent Director · since 2025
Hui Sheng
Independent Director · since 2025
Wenhu Zhang
Independent Director · since 2024
Headquarters & legal address
苏州市吴中区东方大道988号
苏州市, JS 100000
CN
苏州市, JS 100000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||